Galmed Pharmaceuticals
At close: Sep 30
PreMarket: 6:08PM EDT
Day Range- - -52 Wk Range0.3 - 2.18Open / Close- / -Float / Outstanding21.6M / 25.1M
Vol / Avg.- / 88.2KMkt Cap7.8MP/E-50d Avg. Price0.44
Div / Yield-Payout Ratio-Total Float21.6MEPS-0.15

Galmed Pharmaceuticals Stock (NASDAQ:GLMD), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1


Highest Price Target1


Lowest Price Target1


Consensus Price Target1


Analyst Rating Summary1


Analyst Firms Making Recommendations1

  • Maxim Group
  • Raymond James
  • HC Wainwright & Co.

1calculated from analyst ratings published within the last 6 months

Analyst Ratings for Galmed Pharmaceuticals

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert

Galmed Pharmaceuticals Questions & Answers

What is the target price for Galmed Pharmaceuticals (GLMD)?

The latest price target for Galmed Pharmaceuticals (NASDAQ: GLMD) was reported by Canaccord Genuity on May 17, 2021. The analyst firm set a price target for $21.00 expecting GLMD to rise to within 12 months (a possible 6650.24% upside). 5 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Galmed Pharmaceuticals (GLMD)?

The latest analyst rating for Galmed Pharmaceuticals (NASDAQ: GLMD) was provided by Canaccord Genuity, and Galmed Pharmaceuticals maintained their buy rating.

When is the next analyst rating going to be posted or updated for Galmed Pharmaceuticals (GLMD)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on May 17, 2021 so you should expect the next rating to be made available sometime around May 17, 2022.

Is the Analyst Rating Galmed Pharmaceuticals (GLMD) correct?

While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a maintained with a price target of $20.00 to $21.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $0.31, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.